Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vibecotamab |
Synonyms | |
Therapy Description |
Vibecotamab (XmAb14045) is a bispecific antibody that targets CD123 and CD3, potentially resulting in enhanced killing of tumor cells expressing CD133 (Blood 136 (2020): 4-5). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vibecotamab | XmAb14045|SQZ622 | CD3 Antibody 99 | Vibecotamab (XmAb14045) is a bispecific antibody that targets CD123 and CD3, potentially resulting in enhanced killing of tumor cells expressing CD133 (Blood 136 (2020): 4-5). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02730312 | Phase I | Vibecotamab | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | Completed | USA | 0 |